Kidney Transplant Failure and Rejection Clinical Trial
Official title:
Development of a Diagnostic Kit for Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis
The aim of this study is to verify the ability of transglutaminase type 2 to predict rejection or chronic allograft nephropathy of renal allograft. On the basis of biomolecular mechanisms aggravating chronic allograft nephropathy, we eventually expect to develop the remedy to prevent chronic allograft nephropathy after kidney transplantation.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | December 31, 2020 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - kidney transplant recipients from cadaveric or living donors - kidney transplant recipients who take immunosuppressants regularly - kidney transplant recipients who voluntarily agree to participate in this trial Exclusion Criteria: - multiorgan transplant recipients - kidney transplant recipients with active infection - kidney transplant recipients with alcohol or drug addiction |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Asan Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Asan Medical Center |
Korea, Republic of,
Anglicheau D, Muthukumar T, Hummel A, Ding R, Sharma VK, Dadhania D, Seshan SV, Schwartz JE, Suthanthiran M. Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis. Transplantation. 2012 Jun 15;93 — View Citation
Breggia AC, Himmelfarb J. Primary mouse renal tubular epithelial cells have variable injury tolerance to ischemic and chemical mediators of oxidative stress. Oxid Med Cell Longev. 2008 Oct-Dec;1(1):33-8. — View Citation
Brusilovsky M, Radinsky O, Cohen L, Yossef R, Shemesh A, Braiman A, Mandelboim O, Campbell KS, Porgador A. Regulation of natural cytotoxicity receptors by heparan sulfate proteoglycans in -cis: A lesson from NKp44. Eur J Immunol. 2015 Apr;45(4):1180-91. d — View Citation
Halloran PF, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol. 2016 Sep;12(9):534-48. doi: 10.1038/nrneph.2016.85. Epub 2016 Jun 27. Review. — View Citation
Jeong EM, Kim CW, Cho SY, Jang GY, Shin DM, Jeon JH, Kim IG. Degradation of transglutaminase 2 by calcium-mediated ubiquitination responding to high oxidative stress. FEBS Lett. 2009 Feb 18;583(4):648-54. doi: 10.1016/j.febslet.2009.01.032. Epub 2009 Feb — View Citation
Kojima S, Nara K, Rifkin DB. Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol. 1993 Apr;121(2):439-48. — View Citation
Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 2003 Feb;4(2):140-56. Review. — View Citation
Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005 Jan 22-28;365(9456):331-40. Review. — View Citation
Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, Horani A, Nassar M, Friedman SL, Safadi R. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol. 2006 Jul;45(1):60-71. Epub 2006 Feb 8. — View Citation
Oh K, Park HB, Byoun OJ, Shin DM, Jeong EM, Kim YW, Kim YS, Melino G, Kim IG, Lee DS. Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice. J Exp Med. 201 — View Citation
Scarpellini A, Germack R, Lortat-Jacob H, Muramatsu T, Billett E, Johnson T, Verderio EA. Heparan sulfate proteoglycans are receptors for the cell-surface trafficking and biological activity of transglutaminase-2. J Biol Chem. 2009 Jul 3;284(27):18411-23. — View Citation
Scarpellini A, Huang L, Burhan I, Schroeder N, Funck M, Johnson TS, Verderio EA. Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis. J Am Soc Nephrol. 2014 May;25(5):1013-27. doi: 10.1681 — View Citation
Shin S, Kim YH, Cho YM, Park Y, Han S, Choi BH, Choi JY, Han DJ. Interpreting CD56+ and CD163+ infiltrates in early versus late renal transplant biopsies. Am J Nephrol. 2015;41(4-5):362-9. doi: 10.1159/000430473. Epub 2015 Jun 18. — View Citation
Victorino F, Sojka DK, Brodsky KS, McNamee EN, Masterson JC, Homann D, Yokoyama WM, Eltzschig HK, Clambey ET. Tissue-Resident NK Cells Mediate Ischemic Kidney Injury and Are Not Depleted by Anti-Asialo-GM1 Antibody. J Immunol. 2015 Nov 15;195(10):4973-85. — View Citation
* Note: There are 14 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change of level of urinary transglutaminase 2 | 3 days, 7 days, 1 month, 3 months, 6 months post-transplant |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04057742 -
AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation
|
||
Recruiting |
NCT03465397 -
Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients
|
Phase 4 | |
Completed |
NCT03437577 -
Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05282966 -
Assessment of QSantâ„¢ for Underlying Allograft Rejection
|
||
Recruiting |
NCT04388930 -
The Microbiota in Kidney Donation and Transplantation
|
||
Completed |
NCT03611621 -
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
|
||
Recruiting |
NCT05397821 -
Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
|
||
Completed |
NCT04019353 -
Cf-DNA Assay During Treatment of Acute Rejection
|
||
Recruiting |
NCT05806749 -
Immunological Tolerance in Patients With Mismatched Kidney Transplants
|
Phase 1 | |
Recruiting |
NCT04936282 -
Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING)
|
Phase 4 | |
Enrolling by invitation |
NCT05285878 -
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
|
Phase 2 | |
Recruiting |
NCT04526431 -
Tacrolimus Pharmacokinetic Subpopulations
|
||
Active, not recruiting |
NCT03511560 -
Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation
|
Phase 4 | |
Recruiting |
NCT03438773 -
Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients
|
Phase 1 | |
Completed |
NCT05388955 -
Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation
|
||
Completed |
NCT06394596 -
Predicting Prognostic Factors in Kidney Transplantation Using A Machine Learning
|
||
Completed |
NCT04413916 -
MiRNA in Kidney Transplantation: Association With Kidney Graft Function and Disease Process
|
||
Completed |
NCT03466775 -
Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes
|
N/A | |
Active, not recruiting |
NCT04733131 -
Long-term Outcomes After Conversion to Belatacept
|
||
Active, not recruiting |
NCT03380962 -
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
|
Phase 1/Phase 2 |